This article is more than 5 years old. Information may no longer be current.

AmEx Pharmacy recalls one lot of bevacizumab

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

AmEx Pharmacy announced a voluntary recall of one lot of bevacizumab due to a reported defective delivery system, according to a press release.

The Monoject syringe may be difficult to express, and the force needed to express bevacizumab (Avastin, Genentech) could potentially result in damage to the eye. Three reports of the lot being difficult to express, two resulting in adverse drug events, have been reported.

The affected lot is 190212AB, BUD 5/13/2019, and it was distributed to ophthalmologist clinics in Pennsylvania, Illinois, Texas, Wisconsin, Kansas, Tennessee, Indiana and Arizona.

AmEx is notifying all clinics by telephone and overnight mail of the recall and is arranging for return and replacement of the recalled lot. Physicians should stop using the recalled product and return it to AmEx Pharmacy.